Showing 5631-5640 of 7028 results for "".
- AAD Survey: Only a Third of Americans are Concerned about Skin Cancer Despite Nearly 70% Having at Least One Risk Factorhttps://practicaldermatology.com/news/aad-survey-only-a-third-of-americans-are-concerned-about-skin-cancer-despite-nearly-70-having-at-least-one-risk-factor/2460836/Despite skin cancer being the most common cancer in the U.S., only about one-third of adults are concerned about developing the disease, even though nearly 70 percent say they have at least one risk factor for skin cancer, according to a new American Academy of Dermatology (AAD) survey.
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- Nurx Adds Rosacea Care to List of Serviceshttps://practicaldermatology.com/news/nurx-adds-rosacea-care-to-list-of-services/2460832/Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. The expansion builds on the successful launch of Nurx&
- New Research Shows How Immune Cells Organize Themselves in the Epidermishttps://practicaldermatology.com/news/new-research-shows-how-immune-cells-organize-themselves-in-the-epidermis/2460827/New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. Many people don’t realize that the epidermis is home to immune cells. To bring more cla
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a d
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog